Nat Med. 2012 Jun 6;18(6):841. doi: 10.1038/nm0612-841.
Recommendation of HIV test brings diagnostic dilemma home.
"David Paltiel, a public health researcher at the Yale University School of Medicine in New Haven, Connecticut, points out that individuals with the highest risk of HIV tend to be in the lowest income brackets, and OraQuick may cost more than they are willing to pay. So he expects its consumers will probably be well-off individuals “composed disproportionately of HIV-uninfected, 'worried well' persons and very recently infected, undetectable cases.”
The availability of an in-home test “is not going to hurt,” Paltiel says, stressing the benefit to individuals. “But I don't think it's going to help” from a public health standpoint, he notes."
No comments:
Post a Comment